300254 仟源医药
已收盘 11-06 15:00:00
资讯
新帖
简况
股市必读:仟源医药三季报 - 第三季度单季净利润同比下降29.26%
证券之星 · 10-29
股市必读:仟源医药三季报 - 第三季度单季净利润同比下降29.26%
仟源医药:华夏基金、申万宏源等多家机构于10月28日调研我司
证券之星 · 10-28
仟源医药:华夏基金、申万宏源等多家机构于10月28日调研我司
仟源医药(300254)9月30日股东户数1.94万户,较上期增加11.4%
证券之星 · 10-28
仟源医药(300254)9月30日股东户数1.94万户,较上期增加11.4%
图解仟源医药三季报:第三季度单季净利润同比下降29.26%
证券之星 · 10-28
图解仟源医药三季报:第三季度单季净利润同比下降29.26%
仟源医药(300254)10月19日主力资金净买入69.74万元
证券之星 · 10-19
仟源医药(300254)10月19日主力资金净买入69.74万元
仟源医药(300254)308万股限售股将于9月30日解禁,占总股本1.2%
证券之星 · 09-30
仟源医药(300254)308万股限售股将于9月30日解禁,占总股本1.2%
仟源医药(300254)披露向银行申请并购贷款并接受关联方担保的公告,9月29日股价上涨0.11%
证券之星 · 09-29
仟源医药(300254)披露向银行申请并购贷款并接受关联方担保的公告,9月29日股价上涨0.11%
仟源医药(300254)9月28日主力资金净买入441.71万元
证券之星 · 09-28
仟源医药(300254)9月28日主力资金净买入441.71万元
股市必读:仟源医药新发布《关于2025年限制性股票激励计划第一个解除限售期解除限售股份上市流通提示性公告》
证券之星 · 09-28
股市必读:仟源医药新发布《关于2025年限制性股票激励计划第一个解除限售期解除限售股份上市流通提示性公告》
仟源医药(300254)披露2025年限制性股票激励计划第一个解除限售期解除限售股份上市流通提示性公告,9月24日股价下跌1.56%
证券之星 · 09-24
仟源医药(300254)披露2025年限制性股票激励计划第一个解除限售期解除限售股份上市流通提示性公告,9月24日股价下跌1.56%
仟源医药(300254)披露2026年限制性股票激励计划获股东大会审议通过,9月4日股价上涨0.23%
证券之星 · 09-04
仟源医药(300254)披露2026年限制性股票激励计划获股东大会审议通过,9月4日股价上涨0.23%
股市必读:仟源医药新发布《国浩律师(上海)事务所关于仟源医药2026年第三次临时股东会之法律意见书》
证券之星 · 09-04
股市必读:仟源医药新发布《国浩律师(上海)事务所关于仟源医药2026年第三次临时股东会之法律意见书》
仟源医药(300254)披露2026年限制性股票激励计划草案,9月1日股价上涨1.57%
证券之星 · 09-01
仟源医药(300254)披露2026年限制性股票激励计划草案,9月1日股价上涨1.57%
仟源医药:公司将于2026年9月3日召开2026年第三次临时股东会
证券日报 · 09-01
仟源医药:公司将于2026年9月3日召开2026年第三次临时股东会
仟源医药(300254)披露2026年半年度报告,8月25日股价下跌3.04%
证券之星 · 08-25
仟源医药(300254)披露2026年半年度报告,8月25日股价下跌3.04%
仟源医药(300254)6月30日股东户数1.74万户,较上期减少7.38%
证券之星 · 08-25
仟源医药(300254)6月30日股东户数1.74万户,较上期减少7.38%
股市必读:仟源医药新发布《第六届董事会第七次会议决议公告》
证券之星 · 08-19
股市必读:仟源医药新发布《第六届董事会第七次会议决议公告》
股市必读:仟源医药新发布《第六届董事会第七次会议决议公告》
证券之星 · 08-18
股市必读:仟源医药新发布《第六届董事会第七次会议决议公告》
仟源医药(300254)披露2024年限制性股票激励计划第二个解除限售期解除限售股份上市流通提示性公告,7月22日股价下跌1.2%
证券之星 · 07-22
仟源医药(300254)披露2024年限制性股票激励计划第二个解除限售期解除限售股份上市流通提示性公告,7月22日股价下跌1.2%
仟源医药(300254)披露2024年限制性股票激励计划第二个解除限售期解除限售条件成就公告,7月16日股价上涨4.62%
证券之星 · 07-16
仟源医药(300254)披露2024年限制性股票激励计划第二个解除限售期解除限售条件成就公告,7月16日股价上涨4.62%
公司概况
公司名称:
山西仟源医药集团股份有限公司
所属行业:
医药制造业
上市日期:
2011-08-19
主营业务:
山西仟源医药集团股份有限公司的主营业务是医药、保健食品的研发、生产、销售、医疗健康服务及商业业务等。公司的主要产品是磷霉素氨丁三醇散、盐酸坦索罗辛缓释胶囊、依巴斯汀片、酒石酸伐尼克兰片、维生素AD滴剂、盐酸氨溴索分散片、蒙脱石散、盐酸氟西汀胶囊、盐酸西那卡塞片、阿哌沙班片、利伐沙班片、盐酸氨基葡萄糖(原料药)、保灵孕宝口服液、基因保存服务。
发行价格:
13.00
{"stockData":{"symbol":"300254","market":"SZ","secType":"STK","nameCN":"仟源医药","latestPrice":7.57,"timestamp":1793948604000,"preClose":7.73,"halted":0,"volume":5878300,"delay":0,"changeRate":-0.0207,"floatShares":231000000,"shares":271000000,"eps":0.0824,"marketStatus":"已收盘","change":-0.16,"latestTime":"11-06 15:00:00","open":7.54,"high":7.68,"low":7.48,"amount":44562900,"amplitude":0.0259,"askPrice":7.59,"askSize":81,"bidPrice":7.57,"bidSize":246,"shortable":0,"etf":0,"ttmEps":0.0824,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":5,"adr":0,"adjPreClose":7.73,"symbolType":"stock","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":8.5,"lowLimit":6.96,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":271188563,"isCdr":false,"pbRate":4.18,"roa":"--","peRate":91.868932,"roe":"4.81%","epsLYR":0.1024,"committee":0.210114,"marketValue":2053000000,"turnoverRate":0.0255,"status":1,"floatMarketCap":1745000000},"requestUrl":"/m/hq/s/300254/wiki","defaultTab":"wiki","newsList":[{"id":"2679441929","title":"股市必读:仟源医药三季报 - 第三季度单季净利润同比下降29.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679441929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679441929?lang=zh_cn&edition=full","pubTime":"2026-10-29 04:10","pubTimestamp":1793218213,"startTime":"0","endTime":"0","summary":"业绩披露要点:2026年第三季度单季度扣非净利润654.21万元,同比下降70.97%。业绩披露要点财务报告2026年前三季度主营收入5.38亿元,同比下降11.97%;归母净利润1981.07万元,同比下降11.27%;扣非净利润1186.76万元,同比下降32.29%。其中第三季度单季度主营收入1.86亿元,同比下降21.85%;单季度归母净利润1552.48万元,同比下降29.26%;单季度扣非净利润654.21万元,同比下降70.97%;负债率64.41%,投资收益468.08万元,财务费用1839.67万元,毛利率64.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900004852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300254"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678008496","title":"仟源医药:华夏基金、申万宏源等多家机构于10月28日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2678008496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678008496?lang=zh_cn&edition=full","pubTime":"2026-10-28 22:01","pubTimestamp":1793196086,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年10月28日仟源医药发布公告称华夏基金李柄桦、申万宏源仰佳佳 张静含于2026年10月28日调研我司。帕瑞可覆盖线上与线下渠道;家庭药师仅在线下渠道销售, 2026 年公司资源侧重于帕瑞可,家庭药师保持平稳增长。相关情况以股东及公司已披露信息为准。仟源医药主营业务:医药、保健食品的研发、生产、销售及医学诊断、基因保存等医疗健康服务及商业业务等。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800050470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","BK0046","BK0188","BK0077","06806","300254","BK0028","BK0239","BK0042","BK1147","000166","BK0114","BK0183","BK0012","BK1564"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678665534","title":"仟源医药(300254)9月30日股东户数1.94万户,较上期增加11.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678665534","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678665534?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:47","pubTimestamp":1793184452,"startTime":"0","endTime":"0","summary":"证券之星消息,近日仟源医药披露,截至2026年9月30日公司股东户数为1.94万户,较6月30日增加1987.0户,增幅为11.4%。在化学制药行业个股中,仟源医药股东户数低于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.9万户。从股价来看,2026年6月30日至2026年9月30日,仟源医药区间涨幅为14.73%,在此期间股东户数增加1987.0户,增幅为11.4%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800041064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0046","300254","BK0114","BK0239","BK0028","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678107197","title":"图解仟源医药三季报:第三季度单季净利润同比下降29.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678107197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678107197?lang=zh_cn&edition=full","pubTime":"2026-10-28 02:31","pubTimestamp":1793125910,"startTime":"0","endTime":"0","summary":"证券之星消息,仟源医药2026年三季报显示,前三季度公司主营收入5.38亿元,同比下降11.97%;归母净利润1981.07万元,同比下降11.27%;扣非净利润1186.76万元,同比下降32.29%;其中2026年第三季度,公司单季度主营收入1.86亿元,同比下降21.85%;单季度归母净利润1552.48万元,同比下降29.26%;单季度扣非净利润654.21万元,同比下降70.97%;负债率64.41%,投资收益468.08万元,财务费用1839.67万元,毛利率64.39%。财报数据概要请见下图:本文数据来源于仟源医药2026年三季报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800002924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300254"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676505099","title":"仟源医药(300254)10月19日主力资金净买入69.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676505099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676505099?lang=zh_cn&edition=full","pubTime":"2026-10-19 15:34","pubTimestamp":1792395268,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月19日收盘,仟源医药报收于8.37元,下跌2.9%,换手率3.98%,成交量9.17万手,成交额7647.63万元。仟源医药主营业务:医药、保健食品的研发、生产、销售及医学诊断、基因保存等医疗健康服务及商业业务等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900013582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0239","BK0077","BK0028","BK0046","BK0042","300254"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671225866","title":"仟源医药(300254)308万股限售股将于9月30日解禁,占总股本1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671225866","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671225866?lang=zh_cn&edition=full","pubTime":"2026-09-30 08:12","pubTimestamp":1790727179,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,仟源医药于9月30日将有308.0万股限售股份解禁,为公司股权激励限售股份,占公司总股本1.2%。最近一年内,该股累计解禁148.5万股,占总股本的0.58%。本次解禁后,公司还有2670.05万股限售股份,占总股本10.38%。仟源医药主营业务:医药、保健食品的研发、生产、销售及医学诊断、基因保存等医疗健康服务及商业业务等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000006387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0042","BK0114","BK0077","BK0046","300254","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671290750","title":"仟源医药(300254)披露向银行申请并购贷款并接受关联方担保的公告,9月29日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671290750","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671290750?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:36","pubTimestamp":1790674574,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘,仟源医药报收于9.09元,较前一交易日上涨0.11%,最新总市值为23.38亿元。近日,仟源医药披露《关于公司向银行申请并购贷款并接受关联方担保的公告》。公告显示,公司拟向中国工商银行大同分行魏都支行申请两笔并购贷款,总额不超过15,215万元,用于置换收购南通恒嘉34%股权和仟源海力生20%股权的部分价款。黄乐群、赵群为公司关联自然人,本次担保构成关联交易,公司无需支付对价或提供反担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900029158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0114","BK0077","300254","BK0042","BK0046","161121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670428288","title":"仟源医药(300254)9月28日主力资金净买入441.71万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670428288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670428288?lang=zh_cn&edition=full","pubTime":"2026-09-28 15:29","pubTimestamp":1790580547,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月28日收盘,仟源医药报收于9.08元,上涨2.6%,换手率5.78%,成交量13.15万手,成交额1.19亿元。仟源医药主营业务:医药、保健食品的研发、生产、销售及医学诊断、基因保存等医疗健康服务及商业业务等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800014592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0042","300254","BK0239","BK0046","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670740126","title":"股市必读:仟源医药新发布《关于2025年限制性股票激励计划第一个解除限售期解除限售股份上市流通提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670740126","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670740126?lang=zh_cn&edition=full","pubTime":"2026-09-28 03:59","pubTimestamp":1790539147,"startTime":"0","endTime":"0","summary":"公司公告汇总关于2025年限制性股票激励计划第一个解除限售期解除限售股份上市流通提示性公告山西仟源医药集团股份有限公司于2026年9月4日召开董事会,审议通过2025年限制性股票激励计划第一个解除限售期解除限售条件成就的议案。本次解除限售的激励对象共162人,解除限售股份为308万股,占公司总股本的1.20%,上市流通日为2026年9月30日。个人绩效考核中162名激励对象合格,1名不合格,其股份将回购注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0114","BK0042","BK0028","BK0239","300254","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669499284","title":"仟源医药(300254)披露2025年限制性股票激励计划第一个解除限售期解除限售股份上市流通提示性公告,9月24日股价下跌1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669499284","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669499284?lang=zh_cn&edition=full","pubTime":"2026-09-24 22:38","pubTimestamp":1790260697,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘,仟源医药报收于8.85元,较前一交易日下跌1.56%,最新总市值为22.76亿元。近日,仟源医药发布《关于2025年限制性股票激励计划第一个解除限售期解除限售股份上市流通提示性公告》。公告显示,公司于2026年9月4日召开董事会,审议通过2025年限制性股票激励计划第一个解除限售期解除限售条件成就的议案。本次解除限售的激励对象共162人,解除限售股份为308万股,占公司总股本的1.20%,上市流通日为2026年9月30日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400041613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0042","BK0077","BK0114","BK0028","300254"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664333428","title":"仟源医药(300254)披露2026年限制性股票激励计划获股东大会审议通过,9月4日股价上涨0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333428","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664333428?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:41","pubTimestamp":1788514879,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,仟源医药报收于8.7元,较前一交易日上涨0.23%,最新总市值为22.38亿元。公司于近日披露《2026年第三次临时股东会决议公告》。会议由副董事长钟海荣主持,出席会议的股东共108人,代表股份占公司总股本的11.9657%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400031636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0028","BK0114","BK0077","300254","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664080650","title":"股市必读:仟源医药新发布《国浩律师(上海)事务所关于仟源医药2026年第三次临时股东会之法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664080650","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664080650?lang=zh_cn&edition=full","pubTime":"2026-09-04 02:03","pubTimestamp":1788458596,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘,仟源医药报收于8.68元,下跌1.14%,换手率3.06%,成交量6.97万手,成交额6052.1万元。公司公告汇总:2026年限制性股票激励计划内幕信息知情人在自查期间均无买卖公司股票行为。交易信息汇总资金流向9月3日主力资金净流出176.33万元,占总成交额2.91%;游资资金净流出235.15万元,占总成交额3.89%;散户资金净流入411.48万元,占总成交额6.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0042","BK0114","BK0077","BK0046","300254","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664857143","title":"仟源医药(300254)披露2026年限制性股票激励计划草案,9月1日股价上涨1.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664857143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664857143?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:47","pubTimestamp":1788274031,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘,仟源医药报收于9.06元,较前一交易日上涨1.57%,最新总市值为23.3亿元。该股当日开盘8.92元,最高9.08元,最低8.84元,成交额达8919.78万元,换手率为4.37%。上述议案需经出席会议有效表决权股份总数的三分之二以上通过,并对中小投资者单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0114","BK0042","BK0028","BK0077","300254"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664585758","title":"仟源医药:公司将于2026年9月3日召开2026年第三次临时股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2664585758","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664585758?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:47","pubTimestamp":1788270420,"startTime":"0","endTime":"0","summary":"9月1日,仟源医药发布公告称,公司将于2026年9月3日召开2026年第三次临时股东会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-01/doc-iniqitru8352444.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-01/doc-iniqitru8352444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0114","BK0028","BK0239","BK0042","BK0046","BK0077","300254"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662541736","title":"仟源医药(300254)披露2026年半年度报告,8月25日股价下跌3.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662541736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662541736?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:46","pubTimestamp":1787654815,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,仟源医药报收于9.25元,较前一交易日下跌3.04%,最新总市值为23.79亿元。该股当日开盘9.47元,最高9.54元,最低9.05元,成交额达2.79亿元,换手率为13.31%。公司于近日披露《2026年半年度报告》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500039712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0042","BK0046","300254","BK0114","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662219738","title":"仟源医药(300254)6月30日股东户数1.74万户,较上期减少7.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662219738","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662219738?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:52","pubTimestamp":1787651540,"startTime":"0","endTime":"0","summary":"证券之星消息,近日仟源医药披露,截至2026年6月30日公司股东户数为1.74万户,较3月31日减少1389.0户,减幅为7.38%。在化学制药行业个股中,仟源医药股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.68万户。从股价来看,2026年3月31日至2026年6月30日,仟源医药区间跌幅为28.99%,在此期间股东户数减少1389.0户,减幅为7.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500037616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300254","BK0077","BK0042","BK0028","BK0114","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660849912","title":"股市必读:仟源医药新发布《第六届董事会第七次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660849912","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660849912?lang=zh_cn&edition=full","pubTime":"2026-08-19 01:36","pubTimestamp":1787074569,"startTime":"0","endTime":"0","summary":"公司公告汇总第六届董事会第七次会议决议公告仟源医药第六届董事会第七次会议审议通过《2026年限制性股票激励计划(草案)》及其摘要、《2026年限制性股票激励计划实施考核管理办法》、激励对象黄乐群累计获授股份超公司总股本1%、提请股东大会授权董事会办理本次股权激励相关事宜,以及召开2026年第三次临时股东大会的议案。前三项议案因涉及关联董事回避表决,需提交股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300254","BK0114","BK0028","BK0077","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660439055","title":"股市必读:仟源医药新发布《第六届董事会第七次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660439055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660439055?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:00","pubTimestamp":1786986048,"startTime":"0","endTime":"0","summary":"公司公告汇总第六届董事会第七次会议决议公告仟源医药第六届董事会第七次会议审议通过《2026年限制性股票激励计划(草案)》及其摘要、《2026年限制性股票激励计划实施考核管理办法》、激励对象黄乐群累计获授股份超公司总股本1%、提请股东大会授权董事会办理本次股权激励相关事宜,以及召开2026年第三次临时股东大会的议案。前三项议案因涉及关联董事回避表决,需提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800001345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0114","BK0028","BK0042","300254","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653766127","title":"仟源医药(300254)披露2024年限制性股票激励计划第二个解除限售期解除限售股份上市流通提示性公告,7月22日股价下跌1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653766127","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653766127?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:38","pubTimestamp":1784731095,"startTime":"0","endTime":"0","summary":"近日,仟源医药发布《关于2024年限制性股票激励计划第二个解除限售期解除限售股份上市流通提示性公告》。公告显示,公司于2026年7月16日召开第六届董事会第六次会议,审议通过2024年限制性股票激励计划第二个解除限售期解除限售条件成就的议案。本次解除限售的激励对象共46人,解除限售股份198万股,占公司总股本的0.77%。个人绩效考核均合格,解除限售比例为100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0114","BK0042","BK0028","BK0239","300254","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651844029","title":"仟源医药(300254)披露2024年限制性股票激励计划第二个解除限售期解除限售条件成就公告,7月16日股价上涨4.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651844029","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651844029?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:16","pubTimestamp":1784211380,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘,仟源医药报收于9.29元,较前一交易日上涨4.62%,最新总市值为23.89亿元。仟源医药于2026年7月16日发布《关于2024年限制性股票激励计划第二个解除限售期解除限售条件成就的公告》。本次符合解除限售条件的激励对象共46人,解除限售数量为198万股,占公司总股本的0.77%。本次解除限售尚需办理相关手续并履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600040125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300254","BK0042","BK0114","BK0046","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793984657373,"stockEarnings":[{"period":"1week","weight":0.0271},{"period":"1month","weight":-0.1763},{"period":"3month","weight":-0.1198},{"period":"6month","weight":-0.4581},{"period":"1year","weight":-0.2971},{"period":"ytd","weight":-0.252}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":-0.0502},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.127},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":-0.0805}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山西仟源医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19418人(较上一季度增加11.40%)","perCapita":"11870股","listingDate":"2011-08-19","address":"山西省大同市云州区大同经济技术开发区生物科技创新产业园翠微街2号","registeredCapital":"27118万元","survey":" 山西仟源医药集团股份有限公司的主营业务是医药、保健食品的研发、生产、销售、医疗健康服务及商业业务等。公司的主要产品是磷霉素氨丁三醇散、盐酸坦索罗辛缓释胶囊、依巴斯汀片、酒石酸伐尼克兰片、维生素AD滴剂、盐酸氨溴索分散片、蒙脱石散、盐酸氟西汀胶囊、盐酸西那卡塞片、阿哌沙班片、利伐沙班片、盐酸氨基葡萄糖(原料药)、保灵孕宝口服液、基因保存服务。","listedPrice":13},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仟源医药(300254)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仟源医药(300254)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仟源医药,300254,仟源医药股票,仟源医药股票老虎,仟源医药股票老虎国际,仟源医药行情,仟源医药股票行情,仟源医药股价,仟源医药股市,仟源医药股票价格,仟源医药股票交易,仟源医药股票购买,仟源医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仟源医药(300254)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仟源医药(300254)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}